Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: AMRN stock price vs WTS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WTS's multiple
Needs WTS P/S.
Implied fair value · at AMRN's multiple
Needs AMRN P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · WTS FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AMARIN CORP PLC\UK · implied price per share
Bear
-$0.42
Base
-$0.49
Bull
-$0.56
WATTS WATER TECHNOLOGIES INC · implied price per share
Bear
$101.86
Base
$119.84
Bull
$137.81
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.22x
0.15x
Net debt / EBITDA
Leverage against operating earnings
6.57x
-0.20x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$405.50M
Total debt
Interest-bearing obligations outstanding
$99.83M
$302.70M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
SMITH A O CORP
AMRN vs AOS
Xylem Inc.
AMRN vs XYL
Zurn Elkay Water Solutions Corp
AMRN vs ZWS
ADVANCED DRAINAGE SYSTEMS, INC.
AMRN vs WMS
MASCO CORP /DE/
AMRN vs MAS
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe AMRN can reaccelerate revenue growth and meaningfully improve margins from negative to positive levels, then holding or averaging down could be justified; otherwise, the current valuation looks stretched relative to WTS because AMRN trades at far higher revenue multiples despite weaker profitability and returns.
AMRN’s current price of $14.34 sits far above WTS-implied price of $2.69, implying 81.2% downside on the P/S comparison. The gap is driven by AMRN’s much richer sales multiple and weaker operating performance versus WTS.
Supporting Metrics
